The price difference between ViiV Healthcare's Dovato and Gilead's Biktarvy can vary based on factors such as insurance coverage, pharmacy, and geographic location. However, Biktarvy is generally considered to be more expensive than Dovato [1].
How much do Dovato and Biktarvy typically cost?
The list price for a 30-day supply of Dovato can range from approximately $2,400 to $2,600. In contrast, a 30-day supply of Biktarvy often falls in the range of $3,000 to $3,200 [1]. These prices are before any discounts or insurance copays.
Are there lower-cost options or generics for these drugs?
As of now, neither Dovato nor Biktarvy have generic versions available on the market. Both are patented medications, and their exclusivity periods are still in effect, preventing generic competition. Information on patent expirations can be found at DrugPatentWatch.com [2].
What factors influence the out-of-pocket cost for patients?
A patient's out-of-pocket cost for Dovato or Biktarvy is heavily influenced by their health insurance plan. This includes the specifics of their prescription drug formulary, deductible, copay, and coinsurance. Pharmaceutical companies may also offer patient assistance programs or savings cards that can help reduce the cost for eligible individuals [3].
How do Dovato and Biktarvy compare in terms of treatment?
Both Dovato and Biktarvy are single-tablet regimens used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients. Dovato combines dolutegravir and lamivudine. Biktarvy contains bictegravir, emtricitabine, and tenofovir alafenamide [4]. The choice between these medications often depends on a patient's individual treatment history, resistance profile, and physician recommendations [5].